Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983467 | 0.88 | TSHR (0.52) | TSHRTP53MAPTKAT6APOLB | |
| SCHEMBL3981901 | 0.86 | TSHR (0.45) | TSHRTP53MAPTACLYKAT6A | |
| SCHEMBL3982582 | 0.86 | TSHR (0.47) | TSHRTP53MAPTACLYKAT6A | |
| SCHEMBL3986148 | 0.86 | MAPT (0.58) | TSHRTP53MAPT | |
| SCHEMBL3980189 | 0.84 | PTK2B (0.47) | TSHRACLYKAT6APTK2BSMN1; SMN2 | |
| SCHEMBL3983331 | 0.77 | METAP2 (0.50) | TSHRTP53MAPTKAT6A | |
| SCHEMBL3982515 | 0.76 | TSHR (0.45) | TSHRTP53MAPTACLYKAT6A | |
| SCHEMBL3987729 | 0.74 | RAB9A (0.43) | TSHRMAPTCYP2C9 | |
| SCHEMBL3982577 | 0.73 | MAPT (0.60) | TP53MAPT | |
| SCHEMBL3984285 | 0.73 | MAPT (0.57) | TSHRTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | TSHR 4446/4885TP53 1079/4885MAPT 3230/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | TSHR 4446/4885TP53 1079/4885MAPT 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.